Vigil Neuroscience - VIGL Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $17.40
  • Forecasted Upside: 440.37%
  • Number of Analysts: 4
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$3.22
▼ -0.06 (-1.83%)

This chart shows the closing price for VIGL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vigil Neuroscience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VIGL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VIGL

Analyst Price Target is $17.40
▲ +440.37% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Vigil Neuroscience in the last 3 months. The average price target is $17.40, with a high forecast of $24.00 and a low forecast of $4.00. The average price target represents a 440.37% upside from the last price of $3.22.

This chart shows the closing price for VIGL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 4 polled investment analysts is to moderate buy stock in Vigil Neuroscience. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
10/20/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
1/18/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
4/18/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
7/17/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
10/15/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
1/13/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
3/13/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
4/12/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$24.00Low
12/19/2023Morgan StanleyDowngradeEqual Weight ➝ Underweight$13.00 ➝ $4.00Low
11/17/2023WedbushReiterated RatingOutperform ➝ Outperform$23.00Low
11/8/2023WedbushReiterated RatingOutperform ➝ Outperform$23.00Low
10/18/2023JMP SecuritiesInitiated CoverageOutperform$23.00Low
9/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$24.00Low
8/10/2023MizuhoLower Target$15.00 ➝ $13.00Low
8/9/2023HC WainwrightReiterated RatingBuy ➝ Buy$24.00Low
4/3/2023WedbushReiterated RatingOutperform$23.00Low
3/30/2023MizuhoInitiated CoverageBuy$15.00Low
3/27/2023Morgan StanleyBoost TargetEqual Weight$12.00 ➝ $13.00Low
3/22/2023HC WainwrightReiterated RatingBuy$24.00Low
11/14/2022Morgan StanleyBoost TargetEqual Weight$11.00 ➝ $12.00Low
11/11/2022GuggenheimLower TargetBuy$22.00 ➝ $19.00Low
9/15/2022WedbushInitiated CoverageOutperform$19.00Low
8/29/2022HC WainwrightInitiated CoverageBuy$24.00Low
2/1/2022Morgan StanleyInitiated CoverageEqual Weight$17.00High
2/1/2022GuggenheimInitiated CoverageBuy$23.00High
2/1/2022Stifel NicolausInitiated CoverageBuy$24.00High
2/1/2022Jefferies Financial GroupInitiated CoverageBuy$20.00High
(Data available from 4/12/2019 forward)

News Sentiment Rating

0.36 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/15/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/15/2023
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/14/2023
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/14/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/13/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/12/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/13/2024
  • 5 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/12/2024

Current Sentiment

  • 5 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Vigil Neuroscience logo
Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $3.22
Low: $3.11
High: $3.49

50 Day Range

MA: $3.16
Low: $2.75
High: $3.48

52 Week Range

Now: $3.22
Low: $2.53
High: $11.11

Volume

54,159 shs

Average Volume

103,861 shs

Market Capitalization

$118.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.77

Frequently Asked Questions

What sell-side analysts currently cover shares of Vigil Neuroscience?

The following Wall Street research analysts have issued research reports on Vigil Neuroscience in the last twelve months: HC Wainwright, JMP Securities, Mizuho, Morgan Stanley, and Wedbush.
View the latest analyst ratings for VIGL.

What is the current price target for Vigil Neuroscience?

5 Wall Street analysts have set twelve-month price targets for Vigil Neuroscience in the last year. Their average twelve-month price target is $17.40, suggesting a possible upside of 428.9%. HC Wainwright has the highest price target set, predicting VIGL will reach $24.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $4.00 for Vigil Neuroscience in the next year.
View the latest price targets for VIGL.

What is the current consensus analyst rating for Vigil Neuroscience?

Vigil Neuroscience currently has 1 sell rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for VIGL.

What other companies compete with Vigil Neuroscience?

How do I contact Vigil Neuroscience's investor relations team?

The company's listed phone number is 857-254-4445 and its investor relations email address is [email protected]. The official website for Vigil Neuroscience is vigilneuro.com. Learn More about contacing Vigil Neuroscience investor relations.